Abstract
Introduction
Hepatitis B virus (HBV) is a small, enveloped DNA virus that causes chronic hepatitis and often leads to liver cirrhosis and hepatocellular carcinoma (4, 12, 33) . To date, interferon and three nucleoside and nucleotide analogs (lamivudine, adefovir dipivoxil, 65 and entecavir) have been approved by the United States Food and Drug Administration for the treatment of chronic HBV infection. Lamivudine, an oral cytosine nucleoside analogue, potently inhibits hepatitis B virus (HBV) replication by interfering with RNA dependent DNA polymerase (10, 16, 22) . Lamivudine therapy suppresses HBV replication in most patients and improves transaminase levels and liver histology (16, 70 22, 25, 30). However, prolonged therapy results in the emergence of drug-resistant mutants in 24% and 70% of patients after 1 and 4 years of therapy, respectively, followed by increases in viral load and re-elevation of transaminase levels (18).
Most lamivudine-resistant strains show amino acid substitutions in the YMDD (tyrosine-methionine-aspartate-aspartate) motif in the C domain of HBV polymerase. 75 In addition to the emergence of the YMDD mutation, rtL180M and rtV173L mutations in the B domain of HBV polymerase are frequently observed (1, 9) . In vitro analyses have confirmed that the rtL180M mutation augments the level of lamivudine-resistance and enhances viral replication, while the rtV173L mutation enhances only viral replication (9, 23) . On the other hand, only a few uncommon mutations associated with 80 lamivudine-resistance have been reported so far (3, 7, 24, 34) . In the C domain of HBV polymerase, rtM204S and rtD205N were detected in patients with lamivudine resistance (3, 7) . In the B domain, rtL180C and rtA181T were associated with lamivudine resistance (7, 24, 34) . Yeh et al. (34) reported the emergence of rtA181T mutants in 4 of 23 patients who received long-term lamivudine therapy. The mutant 85 appeared concomitantly or after emergence of YMDD motif mutant and persisted thereafter. The nucleotide substitution in the FLLA motif resulted in early termination of overlapping HBs gene by creating a stop codon (TGG to TGA). Yeh et al. (34) demonstrated that the mutation reduced the susceptibility to lamivudine in vitro. They also detected such mutant in a patient with leukemia and speculated that truncated HBs 90 gene might be related to the development of leukemia (7).
A C C E P T E D
Analyzing nucleotide and amino acid sequences of HBV in patients who developed a breakthrough, we identified a novel mutant that showed nucleotide substitutions in the B domain of the reverse transcriptase. The G residues of nucleotides 669 and 670 were substituted to T and A, respectively, and associated with amino acid substitution of 95 rtA181T. The substitutions also induced amino acid substitution W172L into the overlapping HBs protein. Since the nucleotide substitution was associated with nucleotide and amino acid substitution in the putative spacer region of the polymerase, we checked the importance of these substitutions for resistance of lamivudine in vitro.
We also analyzed the resistance of this new strain in vivo using human hepatocyte 100 chimeric mouse (27, 31) . Furthermore, we analyzed the susceptibility of the mutant strain to adefovir and entecavir. When used alone or in combination with lamivudine, these drugs are known to be effective against wild-type as well as lamivudine-resistant HBV (2, 5, 14, 17, 32) . Infrequent emergence compared with lamivudine has been reported for both of these two drugs (2, 5) . We also developed a detection system to 105 identify this novel and previously reported (7, 34) nucleotide substitutions to study the 
Analysis of virological markers
HBsAg, HBeAg and antibody against HBeAg (anti-HBe) were determined by enzyme immunoassay kits (Abbot Diagnostics, Chicago, IL). HBV-DNA was measured by 120 real-time PCR using the Light Cycler (Roche, Mannheim, Germany) by the polymerase chain reaction (PCR). The primers used for amplification were 5'-TTTGGGCATGGACATTGAC-3' and 5'-GGTGAACAATGTTCCGGAGAC-3'.
The amplification condition included initial denaturation at 95℃ for 10 minutes, followed by 45 cycles of denaturation at 95℃ for 15 seconds, annealing at 58℃ for 5 125 seconds and extension at 72℃ for 6 seconds. The lower detection limit of this assay was 300 copies. (patient's strain). In brief, the PCR product amplified using serum from the patient was cleaved with BamHI and ApaI (HBV positions 1400-2600) and cloned into pcDNA3 (Invitrogen, San Diego, CA), which was named pcDNA3-1. Similarly, the PCR product was cleaved with ApaI and BamHI (HBV positions 2600-3215, 1-1400) and cloned into pBluerscript SK+(Stratagene, La Jolla, CA), which was named pB-1. KpnI-BamHI 140 fragment from pB-1 and KpnI-ApaI fragment from pcDNA3-1 were cloned into pcDNA3-1. Finally, the plasmids were cleaved with HindIII and NotI within the multi-cloning site, and cloned into a plasmid vector pTRE. As a laboratory strain, we employed a plasmid containing 1.4 genome length wild type genotype C HBV (wild type strain; GenBank accession number AB206816) (31). To introduce the nucleotide 145 substitutions into the S331C/rtA181T (pt) and wt (lab), site-directed mutagenesis was performed using the QuickChange Site-Directed Mutagenesis kit (Stratagene). The eight plasmids with/without amino acid substitutions in the spacer and reverse transcriptase domain were created and listed in Table 1 . provided by the manufacturer. Quantitative analysis was performed by real-time PCR with cyber green using Light Cycler. The HBV-specific primers used for amplification were 5'-TTTGGGCATGGACATTGAC-3' and 5'-GGTGAACAATGTTCCGGAGAC-3'. The amplification condition included initial denaturation at 95℃ for 10 minutes, followed by 45 cycles of denaturation at 95℃ for 180 15 seconds, annealing at 58℃ for 5 seconds and extension at 72℃ for 6 seconds. The lower detection limit of this assay was 300 copies.
Cloning of HBV DNA and plasmid construction

Evaluation of effects of antiviral drugs on mutant strains using human hepatocyte chimeric mice
185
Human hepatocyte chimeric mice were generated and used in the drug evaluation at 58℃ for 1 min, extension at 72℃ for 2 min), followed by final extension at 72℃ for 7 min. Two μl of PCR products were digested with five units of restriction enzyme EspI and subjected to electrophoresis in a 3.5 % agarose gel. 215 
Statistical analysis
Data are expressed as mean±SD. Group comparisons were performed using the Student t-test. A P value of less than 0.05 was considered statistically significant. 
A C C E P T E D
Results
220
Isolation of a novel lamivudine-resistant strain with intact YMDD motif
The novel lamivudine-resistant strain of HBV was isolated from a 44-year-old Japanese man with chronic HBV infection (Fig. 1A) . In this patient, lamivudine successfully reduced the HBV at the initial stage of treatment, but viral breakthrough was observed at 24 months after the beginning of therapy. The patient was very punctual and 225 confirmed that he took lamivudine with perfect compliance. The HBV viral load reached up to 8.5 log copies/ml, but nucleotide sequence analysis showed no YMDD mutation. The YIDD or YVDD mutants were not detected even by using a PNA-mediated PCR clamping method sensitive for detection of YMDD mutants (6).
The analysis also showed that this isolate belonged to genotype C of HBV. Comparison (Fig. 2) . Twelve HBV genomes were cloned from the serum of this patient after viral breakthrough and eleven of them showed the above amino acid substitutions. Only one clone showed wild type sequence. The new strain of HBV became undetectable when lamivudine therapy was discontinued and this strain out-competed the wild type strain upon re-administration of the drug (Fig.1B) . These results prompted us to study the 240 significance of each of these mutations. 
A C C E P T E D
Effect of substitutions on HBV replication
To assess the effect of nucleotide substitutions on HBV replication, four plasmids containing 1.4 genome length patient-specific HBV genome (Table 1) were generated 245 and transfected into HepG2 cells. In comparison with the patient's wild type strain, the replication capacities of the S331C, rtA181T and S331C/rtA181T mutants were not different (94%, 82% and 96%, respectively), suggesting that these mutants can replicate at almost the same rate as the wild type strain (Fig. 3) .
250
Susceptibility of mutants to lamivudine in vitro
To analyze the role of the polS331C and rtA181T mutations in lamivudine resistance, four patient-specific strains and four laboratory strains were transfected into HepG2 cells (Fig. 4, Table 1 ). A single amino acid substitution in the spacer region did not contribute to resistance in both patient and laboratory strains. In contrast, amino acid 255 substitution in the polymerase (rtA181T) induced 3.0-and 3.9-times greater resistance than patient and laboratory strains (p<0.001), respectively. The presence of both of these amino acid changes induced 3.0-and 4.3-times greater resistance to each of the above strain. Thus, the spacer mutation had little effect on the susceptibility to lamivudine (Table 1) . 260 We also compared the rtA181T mutant identified in this study with the rtA181T mutant reported previously, which had premature termination in the HBs protein (7, 34), for replication ability and susceptibility to lamivudine. Although the production of HBs antigen to culture supernatants were different between the two strains (52.5±8.2 and 4.4±0.6 IU/ml, respectively), there was no noticeable difference in replication ability 265 and lamivudine sensitivity between the two mutants (data not shown).
A C C E P T E D
Assessment of drug resistance of novel mutations in vivo using human hepatocyte chimeric mice
To confirm the lamivudine resistance of the novel mutant strain, two human hepatocyte 270 chimeric mice were each inoculated with a serum sample obtained from the patient who developed breakthrough without mutations in the YMDD motif (Fig. 1A) . The serum was obtained during breakthrough while the patient was still taking the drug. Twelve weeks after the inoculation of the serum samples, both mice developed high level viremia (7.8 and 6.6 log copies/ml, respectively). Direct sequence analysis showed that 275 the nucleotide sequence of the virus that replicated in the chimeric mice was in accordance with the mutant strain. Cloning and sequencing analysis showed that only one of 12 clones obtained from the inoculum was wild type; while the remaining eleven clones were rtA181T mutant with intact YMDD motif. We also analyzed the serum of the two infected mice before and after lamivudine therapy. All 11 and 15 clones before 280 and all 11 and 12 clones during therapy had rtA181T mutation (data not shown). Two other mice were inoculated with wild type HBV obtained from a patient not treated with lamivudine as a control, and both mice also developed high level viremia (8.3 and 9.3 log copies/ml, respectively). Thirteen weeks later, the viremia reached plateau and the mice were fed food containing lamivudine. After six weeks of treatment, the mean viral 285 load decreased by 2.8 log copies/ml in the wild type, whereas it decreased by only 0.39 log copies/ml in the mutant (p<0.001, Fig. 5 ). 
A C C E P T E D
Susceptibility of mutants to adefovir and entecavir in vitro
We also analyzed the effects of adefovir and entecavir against the S331C/rtA181T 290 mutant using transient transfection assay with HepG2 cells. The IC 50 values of the mutant strain and wild type for both of these two drugs were almost the same ( Table 2) .
Detection of rtA181T mutant in patients treated with lamivudine
In this study, we developed a PCR-RFLP method to detect the rtA181T mutants, by 295 which we were able to detect mutant strains even when mixed with the wild type (Fig.   6 ). The system also detected the rtA181T (HBs stop) mutant reported by Chien et al. (7) and Yeh et al. (34) . Using this method, we analyzed 40 patients who showed viral breakthrough (increase in viral load equal or more than one log) during lamivudine therapy. We found that only one of these 40 patients was positive (Fig. 6A) . Nucleotide 300 sequence analysis of serum samples obtained from this patient showed that the mutant strain had rtA181T mutation with truncated HBs antigen, as reported previously (7, 34).
The YMDD motif of HBV detected in this patient was of the wild type. All 39 remaining patients with viral breakthrough were positive for YIDD and/or YVDD mutants. The PCR-RFLP analysis of these 39 samples showed that four of these 305 samples contain small amount of rtA181T mutants (Fig. 6B) . Nucleotide sequence analyses of these samples showed that they contained only a small amount of rtA181T mutants with truncated HBs antigen (Fig. 6C) . copies/ml after six months of treatment). None of these patients tested positive for both of these mutations (data not shown). 
A C C E P T E D
Discussion
In this study, we identified a novel lamivudine-resistant strain of HBV with intact 315 YMDD motif in a patient who received long-term lamivudine therapy. YMDD mutant was not detected even by using sensitivity enhanced detection method, which was reported previously by our group (6). The double nucleotide substitutions (GG to TA) induced amino acid substitutions in both polymerase (rtA181T) and HBs antigen (HBs W172L). One may assume that the compliance of the patient was poor. However, the 320 patient was very punctual and swore that he took lamivudine with perfect compliance.
Our study demonstrated that the rtA181T mutation reduced the susceptibility to lamivudine by 3.0 -3.9-fold in vitro (Table 1) . Furthermore, we also confirmed lamivudine resistance of this mutant strain in vivo using the human hepatocyte chimeric mice. The amino acid substitution in the RT domain is similar to that reported 325 previously (7, 34). However, in contrast to our results, the mutant strains in the latter reports emerged with or after the mutation in the YMDD motif mutants (YIDD or YVDD) and took over them (34). There are two additional different points between the substitutions we identified and those of Yeh et al (34) . Firstly, the HBs antigen was prematurely terminated in the mutant strain reported by Yeh et al (34) . In this regard, a to replicate in vivo supplied HBs antigen from wild type strains as helper. In contrast, the novel strain identified in this study had no premature termination of HBs gene. The in vitro study suggested that the strain had similar replication ability compared with wild type. Furthermore, we also showed that the strain infected and reached high viral load in human hepatocyte chimeric mice. Although the inoculum contained only a small 340 amount of wild type strain (one of 12 clones), all clones obtained from mouse serum were mutant strain (rtA181T). Considering these results and the fact that the index patient showed high viral titer after breakthrough (more than 7.6 log copies/ml), this mutant strain can spread and replicate by itself and had strong replicative ability.
Secondly, the substitutions identified in this study appeared with nucleotide and 345 amino acid substitution in the spacer region of the polymerase (S331C). There are only a few studies that reported the function of the spacer domain (19, 21, 28) , leaving the biological significance of this region unknown. The substitution in the spacer region reappeared with the A181T mutation in the RT domain in the index patient after restarting lamivudine therapy. Although our study showed no significant contribution vitro study indicated that the rtA181T mutant had no resistance against adefovir and the animal study showed that the combination therapy with lamivudine and adefovir effectively reduced the virus load in woodchuck (15), such combination therapy did not produce sufficient suppression of HBV in the index patient (Fig. 1A) . Amino acid substitution at position 181 has to be further analyzed with regard to resistance against 365 anti-HBV drugs.
The rtA181T mutation detection system using PCR-RFLP developed in this study is a useful tool as we were able to distinguish wild type from all mutants with nucleotide substitutions at the region. The system also enabled us to monitor the fluctuation of wild/mutant ratio during antiviral therapy against HBV (Figs. 1 and 6 ).
370
The incidence of rtA181T mutants with intact YMDD motif is rare in Japanese patients with chronic HBV infection treated with lamivudine. Interestingly, 4 of the 39 (10%) patients who developed lamivudine breakthrough and were positive for YMDD mutants were found to have small amount of rtA181T mutant strains. Different from the previous report (34), the mutants did not take over another strain and were not preceded 375 by exacerbation. We have to follow up these patients carefully for further population change of mutants and for exacerbation of hepatitis.
A recent study reported that the prevalence of genotype A HBV infection is increasing in Japan and the incidence of disease chronicity is higher than other genotypes (26). It is thus expected that increasing number of sexually active population 
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